Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Adjuvant oncology approval expands IO + HIF-2α combo in clear cell kidney cancer

June 14, 2026

The FDA approved pembrolizumab plus belzutifan as an adjuvant treatment for adults with high-risk clear cell renal cell carcinoma after surgery, Dana-Farber said via the approval announcement...

Ebola vaccine acceleration for a specific virus species using mRNA

June 14, 2026

Moderna and CEPI said they are advancing an investigational mRNA vaccine targeting Bundibugyo virus, the rare Ebola virus species linked to the ongoing outbreak in the Democratic Republic of the...

Biotech IPO momentum with record-sized public listings

June 14, 2026

Parabilis Medicines completed a record IPO on Nasdaq, raising $670 million as detailed in the provided content, adding to a rapid run of large biotech listings. The post notes Parabilis’ listing...

Lung inflammation pathway links GPR84 to PANoptosome activation in influenza

June 14, 2026

A new study reported a mechanistic link between the receptor GPR84 and lung inflammation through ZBP1-PANoptosome activation in the context of influenza A virus infection, as described in the...

New immuno-cell therapy stage for liver cancer moves into confirmatory development

June 14, 2026

Oricell advanced its GPC3-targeted autologous CAR T therapy, Ori-C101, into a confirmatory registration phase II trial for GPC3-positive advanced hepatocellular carcinoma, according to the...

Ultrasound-mediated redosable genetic medicines funding expands clinical plans

June 14, 2026

SonoThera raised $125 million in an oversubscribed Series B to advance ultrasound-mediated genetic medicines, using its RIPPLE delivery and PORE payload engineering platform, per the provided...

Partial reprogramming gene therapy enters first-in-human glaucoma trial

June 14, 2026

Life Biosciences said it has treated the first participant in a gene therapy trial designed for partial cellular reprogramming, reported in the provided content. The approach turns on three genes...

Rare disease sequencing workflow reaches broader Netherlands implementation stage

June 14, 2026

Researchers at Radboud University Medical Center and Maastricht University presented early implementation results at the European Society of Human Genetics meeting showing that long-read genome...

GLP-1 safety signal extends to hypotensive events and altered behavior in real-world cohorts

June 14, 2026

Northwestern Medicine researchers reported a safety concern for GLP-1 receptor agonists, linking the drugs to higher incidence of fainting and dizziness, per the provided content. The report...

FDA approval – perioperative IO + HIF-2α in RCC

June 14, 2026

The FDA has approved pembrolizumab (Keytruda) plus belzutifan (Welireg) as an adjuvant treatment for adults with high-risk clear cell renal cell carcinoma after surgery, according to a...

Regulatory dispute – Amgen’s Tavneos bid to stay on market

June 14, 2026

Amgen has asked the FDA for continued approval review of Tavneos (avacopan), arguing the drug’s risk-benefit profile supports keeping it on the market amid concerns raised by the agency. The FDA’s...

Clinical data – first pivotal-stage GPC3 CAR-T for liver cancer

June 14, 2026

Oricell’s glypican-3 (GPC3)-targeted autologous CAR T, Ori-C101, has moved into a confirmatory registration Phase 2 trial for GPC3-positive advanced hepatocellular carcinoma. The company positions...

Clinical trial – single-dose mRNA vaccine protects against Andes hantavirus in animals

June 14, 2026

Researchers at UTMB reported that an Andes hantavirus mRNA vaccine provides full protection after a single dose in a golden Syrian hamster model. The work, published in The Lancet, builds on...

Platform + funding – ultrasound-mediated genetic medicines raise Series B

June 14, 2026

SonoThera raised $125 million in an oversubscribed Series B round to advance ultrasound-mediated delivery of genetic medicines for Duchenne muscular dystrophy (DMD) and autosomal dominant...

Precision medicine tools – long-read sequencing streamlines rare disease diagnostics

June 14, 2026

Implementation results presented at the European Society of Human Genetics meeting in Gothenburg show that first-tier long-read genome sequencing can reduce follow-up testing and shorten time to...

AI + diagnostics workflow – DNA analysis via long-read sequencing expands

June 14, 2026

Radboud University Medical Center and Maastricht UMC+ published clinical long-read genome sequencing work using a comprehensive rare-disease test design, aiming to improve accuracy and efficiency...

Oncology – engineered oncolytic VSV targets metastatic ovarian cancer

June 14, 2026

Researchers reported ErbB-OSV, an engineered vesicular stomatitis virus variant designed to selectively target metastatic ovarian cancer while sparing normal tissue. The study describes a...

Regulatory action / drug safety – GLP-1s linked to hypotensive events

June 14, 2026

Northwestern Medicine researchers reported a safety signal tying GLP-1 receptor agonists to increased incidence of fainting and dizziness, consistent with more hypotensive events. The finding adds...

Biopharma dealmaking – China drives biggest biopharma deal month since 2023

June 14, 2026

Biopharma deal value surged in the first five months of 2026, reaching $135.36 billion—above every prior year through the same window—and May delivered the year’s biggest month at $41.78 billion....

Regulatory approval in oncology

June 14, 2026

The FDA cleared an adjuvant regimen combining pembrolizumab with belzutifan for adults with high-risk clear cell renal cell carcinoma following surgery to remove all or part of the kidney. The...